84 133

Cited 0 times in

Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry

Authors
 Jun Sik Yoon  ;  Han Ah Lee  ;  Jun Yong Park  ;  Bo Hyun Kim  ;  In Joon Lee  ;  Young Eun Chon  ;  Suk Kyun Hong  ;  Dong Hyeon Lee  ;  Hyun-Joo Kong  ;  Young-Joo Won  ;  Eunyang Kim  ;  Jeong-Hoon Lee 
Citation
 Journal of Liver Cancer (대한간암학회지), Vol.20(1) : 41-52, 2020-03 
Journal Title
Journal of Liver Cancer(대한간암학회지)
ISSN
 2288-8128 
Issue Date
2020-03
Keywords
Hepatocellular carcinoma ; Epidemiology ; Overall survival ; Hepatitis B ; Korea
Abstract
Backgrounds/Aims

Backgrounds/Aims: In Korea, hepatocellular carcinoma (HCC) is the sixth most common cancer and results in the second-highest cancer death rate among all cancers. We aimed to describe the characteristics of patients who were newly diagnosed with HCC in Korea between 2008 and 2011.


Methods

The Korean Primary Liver Cancer Registry (KPLCR) is a random sample consisting of approximately 15% of patients with newly diagnosed primary liver cancer registered in the Korean Central Cancer Registry. We investigated the baseline characteristics, treatment modalities, and overall survival (OS) of patients with HCC registered in the KPLCR between 2008 and 2011.


Results

A total of 6,083 patients were histologically or radiologically diagnosed with HCC. The hepatitis B virus was the predominant HCC etiology (72.0%). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, stages 0, A, B, C, and D accounted for 8.6%, 39.7%, 11.5%, 33.8%, and 6.9%, respectively. Transarterial therapy (41.7%) was the most commonly performed initial treatment, followed by best supportive care (21.7%), surgical resection (16.7%), and local ablation therapies (10.6%). The overall rate of adherence to the BCLC treatment guideline was only 37.7%. The 1-, 3-, and 5-year OS rates were 65.6%, 46.2%, and 36.8%, respectively.


Conclusions

Between 2008 and 2011, approximately half of patients with HCC (48.3%) were candidates for curative treatment (BCLC stage 0 or A), but one-third of patients (33.8%) had advanced HCC (BCLC stage C). Transarterial therapy was the most commonly conducted initial treatment and the 5-year OS rate was 36.8% in this period.
Files in This Item:
T202002801.pdf Download
DOI
10.17998/jlc.20.1.41
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/179042
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links